MAP2K7 and cancer: The novel MEK inhibitor tunlametinib in combination with KRASG12C inhibitor AMG510 demonstrated high activity in preclinical xenograft models of KRAS-mutant cancers, rendering a potentially effective treatment for RAS-mutant cancers in clinic.